Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: August 2016

Gov. Christie Says Decision on Ending NJ-PA Tax Pact Coming Soon

Tax 1040Trenton, NJ, August 31, 2016 — David Levinsky reports in the Burlington County Times that Gov. Chris Christie says he’s close to making a decision on whether to end a nearly 40-year-old reciprocal income-tax agreement with Pennsylvania that spares residents who commute across the Delaware River for work from being taxed by the neighboring state.

Gov. Christie has been considering ending the pact since July, when he issued an executive order directing the state treasurer and attorney general to study the issue and the potential impacts.

He told reporters this week that he expected to reach a decision soon, after saying he was still reviewing the issue earlier this month. Continue reading

With Clock Ticking, Obama Administration Proposes Health Law Tweaks and Fixes

Obamacare Health InsuranceWashington, DC, August 31, 2016 — The Associated Press reported that, in one of its last chances to tinker with President Obama’s signature health care law, the Obama administration Monday proposed a series of fixes and adjustments for 2018, when the White House will have a new occupant.

The changes are detailed in a highly technical draft regulation, nearly 300 pages long. Insurers and consumer advocates were trying to decipher its implications Monday evening.

The proposal would update the health insurance marketplace’s premium stabilization system to reflect concerns that insurers have raised. Continue reading

Growing Antibiotic Resistance Forces WHO to Update Recommended Treatment for Sexually Transmitted Diseases

WHOGeneva, Switzerland, August 31, 2016 — New guidelines for the treatment of three common sexually transmitted infections (STIs) have been issued by the World Health Organization (WHO) in response to the growing threat of antibiotic resistance.

Chlamydia, gonorrhea and syphilis are all caused by bacteria and are generally curable with antibiotics. However, these STIs often go undiagnosed and are becoming more difficult to treat, with some antibiotics now failing as a result of misuse and overuse.

It is estimated that, each year, 131 million people are infected with chlamydia, 78 million with gonorrhea, and 5.6 million with syphilis. Continue reading

Governor Christies Announces Over Half a Million New Jerseyans Have Comprehensive Health Care Thanks to Medicaid Expansion

Governor Chris Christie

Governor Chris Christie

Trenton, NJ, August 30, 2016 — Governor Christie yesterday announced that more than half a million New Jerseyans have comprehensive health care coverage who otherwise would not have due to his decision to opt for Medicaid expansion.

The NJ FamilyCare 2015 Annual Report, which details the condition of the state’s medical public assistance program, shows that since the January 2014 expansion, 566,655 more New Jersey residents are now enrolled, thanks to the expansion that has reduced costs for taxpayers and beneficiaries.

  • 336,141 Newly eligible adults
  • 101,644 Previously eligible but not enrolled adults and children
  • 128,870 Adults maintaining eligibility solely due to the state’s decision to expand Medicaid Continue reading

House Oversight Committee Starts Investigating EpiPen Price Hikes; Third Capitol Hill Panel to Dig into Mylan’s Pricing

Capitol Building flagWashington, DC, August 30, 2016 — Catherine Ho reports in The Washington Post that the U.S. House Oversight and Government Reform Committee has launched an investigation into drug maker Mylan, which is facing intense public and political scrutiny for raising the price of its lifesaving EpiPen allergy injection.

The price of an EpiPen two-pack has risen from less than $100 in 2007, the year Mylan acquired the device, to $608 today.

The House Oversight Committee is the third congressional committee to press Mylan on its pricing practices.   Continue reading

GEN Publishes 2016 Top 10 U.S. Biopharma Clusters List; New Jersey/New York Ranked No. 3

New Jersey pin horizontalNew Rochelle, NY, August 29, 2016Genetic Engineering & Biotechnology News (GEN) published its 2016 Top 10 US Biopharma Clusters list.  New Jersey/New York is number three on the list, the same position it was on GEN’s 2015 Top 10 list.

This year’s Top 10 are:

  1. Boston-Cambridge
  2. San Francisco Bay Area
  3. New Jersey/New York
  4. Maryland/DC Metro
  5. San Diego
  6. Greater Philadelphia
  7. Seattle
  8. Raleigh/Durham
  9. Los Angeles/Orange County
  10. Chicagoland Continue reading

FDA Advises Testing for Zika Virus in All Donated Blood and Blood Components in the U.S.

FDA blueWashington, DC, August 28, 2016 — As a further safety measure against the emerging Zika virus outbreak, the U.S. Food and Drug Administration  (FDA) on Friday issued a revised guidance recommending universal testing of donated Whole Blood and blood components for Zika virus in the U.S. and its territories.

“There is still much uncertainty regarding the nature and extent of Zika virus transmission,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.  “At this time, the recommendation for testing the entire blood supply will help ensure that safe blood is available for all individuals who might need transfusion.” Continue reading

BF Business Facilities: 60 Seconds with Choose New Jersey CEO Michele Brown

Michele Brown

Michele Brown

Tinton, NJ, August 27, 2016 — Michele Brown, President and CEO, Choose New Jersey, Inc., sat down with the staff of  BF Business Facilities to discuss incubators, innovation zones, STEM education, incentives and the Garden State in a post-Panamax world.

BF: NJ has established five incubator centers in the state for tech start-ups. Are each of them targeting a different growth sector?

MB: New Jersey is committed to nurturing start-up companies in our key industries and has an extensive network of incubators, accelerators and co-working spaces to support them.

The Commercialization Center for Innovative Technologies (CCIT) is one of the most significant incubation facilities in the U.S. dedicated to life sciences and biotechnology. Located in the heart of New Jersey’s Continue reading

Lenzie Harcum Joins EDA’s Commercialization Center for Innovative Technologies

Lenzie Harcum

Lenzie Harcum

Trenton, NJ, August 26, 2016 — Corey McDonald report in The Star-Ledger/NJ.com that Jersey City resident Lenzie Harcum has joined the state Economic Development Authority (EDA) as the manager of its Commercialization Center for Innovative Technologies (CCIT), the agency announced.

Located between New Jersey’s two research bases — Rutgers and Princeton universities — CCIT is considered one of the most significant incubation facilities in the nation dedicated to life sciences and biotechnology companies.

Harcum will be responsible for all aspects of developing and administering CCIT programming. Continue reading

HHS Says Obamacare Remains Affordable in New Jersey Despite Higher Rates and Fewer Insurers

Obamacare 3Trenton, NJ, August 25, 2016 — Kathleen O’Brien and Jonathan D. Salant report today in The Star-Ledger that increased subsidies should offset the rising cost of Obamacare premiums and allow more than half of New Jerseyans buying insurance through the federal website to pay no more than $75 a month.

That would hold true even if premiums jump by as much as 25 percent, officials of the U.S. Health and Human Services Department said on a conference call Wednesday.

That would be three times greater than the expected average increase of 8 percent by the three companies that sell plans in New Jersey through the federal website established under the Affordable Care Act. Continue reading